Pediatrics, Hematology-Oncology

• 

  People

  • Administrative Positions

    • Wagner, Lars Martin, Chief, Division of Hematology/Oncology

  • Primary Appointments

    • Deel, Michael D, Assistant Professor of Pediatrics
    • Falletta, John Matthew, Professor Emeritus of Pediatrics
    • Kreissman, Susan Gail, Professor of Pediatrics
    • Landi, Daniel Bryce, Assistant Professor of Pediatrics
    • Linardic, Corinne Mary, Associate Professor of Pediatrics
    • Noyd, David, Adjunct Assistant Professor in the Department of Pediatrics
    • Robles, Joanna Maria, Assistant Professor of Pediatrics
    • Rosoff, Philip Martin, Professor Emeritus of Pediatrics
    • Rothman, Jennifer Ann, Associate Professor of Pediatrics
    • Schroeder, Kristin M., Assistant Professor of Pediatrics
    • Sun, Jessica Muller, Assistant Professor of Pediatrics
    • Van Mater, David Sinclaire, Assistant Professor of Pediatrics
    • Wagner, Lars Martin, Professor of Pediatrics

  • Secondary Appointments

    • Ashley, David Michael, Professor in Pediatrics
    • Jordan, Megan, Assistant Professor in the Department of Pediatrics
    • Shah, Nirmish Ramesh, Associate Professor in Pediatrics
    • Strouse, John J., Associate Professor in the Department of Pediatrics
• 

  Administers Grant

  • 2018 ALSF Million Mile Grant
  • A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma (CL-PTL-130)
  • A Novel Hippo-Notch axis controlling embryonal rhabdomyosarcoma tumorigenesis
  • A Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3b) inhibitor
  • A Phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occl
  • A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
  • A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immun
  • A Phase I trial of pomalidomide for children with recurrent, progressive or refractory CNS tumors
  • A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
  • A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
  • A phase II, open-label, non-controlled, intrapatient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naiive severe aplastic anemia or rec
  • AALL1131 Supplemental PCR
  • AG348-C-023
  • AIDS MALIGNANCY CONSORTIUM
  • ALTE15N2 STUDY
  • Acid Sphingomyelinase Activation in Apoptosis
  • An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors (CLOVER-2)
  • Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
  • COG WORK ORDER: (PROJECT: EVERYCHILD (APEC14B1) PCR - COG FOUNDATION
  • COG WORK ORDER: (PROJECT: PEDIATRIC MATCH (APEC1621SC) PCR - COG FOUNDATION
  • COG WORK ORDER: BIQSFP AALL1131
  • COG Work Order AALL07P1--Millennium Pharmaceuticals, Inc.
  • COG Work Order AAML: 1031--Millennium Pharmaceuticals, Inc.
  • COG Work Order: AALL1131: Ph III Clofarabine in High Risk B ALL
  • COMMITTEE LEADERSHIP: NIH National Clinical Trials Network (NCTN) Grant
  • Collection And Storage Centers For Clinical Research...
  • Committee Leadership: COG NCTN Network Group Operations Center
  • Committee Leadership: COG NCTN Network Group Operations Center
  • Cyclophosphamide Resistance In Medulloblastoma
  • Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma
  • Development of RNAi-based therapeutics to target oncogenic lncRNAs in rhabdomyosarcoma
  • Development of peptide vaccine for diffuse intrinsic pontine glioma
  • Dissecting the role of injury is sarcoma formation
  • Dissecting the role of injury is sarcoma formation
  • Effect Of Swainsonine On Human Bone Marrow Stem Cells Trea
  • Effect Of Swainsonine On Human Bone Marrow Stem Cells Trea
  • Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
  • Expansion of the AYA Oncology Initiative at Duke University
  • FACTOR Conference Travel Award
  • Faces of Research 2020
  • Gamete Preservation in Males Receiving Gametotoxic Chemotherapy
  • Generating a mouse model of CIC-rearranged Ewings-like sarcoma
  • Gluathione Modulation Of Alkylators In Medulloblastoma
  • Glutathione Modulation Of Alkylators In Medulloblastoma
  • ICON 1
  • ITP-APPS (Immune ThrombocytoPenia Association of Platelet Parameters Study)
  • Identification and validation of the PAX3-FOXO1 protein interactome
  • Implementing Family Psychosocial Risk Screening for Pediatric Health Equity
  • Investigating co-activator TAZ as a regulator of PAX3-FOXO1, cancer cell stemness, and chemoresistance in fusion-positive rhabdomyosarcoma
  • Investigating the role of Hippo/MST kinases in alveolar rhabdomyosarcoma cancer cell stemness
  • Investigating the role of the transcriptional coactivator TAZ in alveolar rhabdomyosarcoma
  • Longitudinal, multimodal assessment of neuropsychological functioning in children diagnosed with high-risk lymphoblastic leukemia (HR-ALL): Using early changes to predict later impairment (ALTE07C1)
  • MAIN STUDY: Developing Evidence-Based Crieteria for Initiating Treatment fo NF1-OPG.
  • Melphalan Cytotoxicity And Resistance In Medulloblastoma
  • Modeling tumor heterogeneity and therapy resistance in osteosarcoma using patient-derived organoids
  • Molecular Modeling of Pediatric Skeletal Muscle Tumors
  • NCI Community Oncology Research Program (NCORP) Research Base Grant
  • NCI Community Oncology Research Program (NCORP) Research Base Grant
  • NIH COG Pediatric Early Phase Clinical Trial Network Grant (PEP-CTN)
  • NPFC Sunshine Project
  • Neurobiology And Rational Therapy Of Human Medulloblasto
  • Neurobiology And Rational Therapy Of Human Medulloblastoma
  • Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
  • Novel regulators of checkpoint adaptation in fusion-positive rhabdomyosarcoma
  • Novel vulnerabilities within PAX3-FOXO1 transcriptional programming for fusion-positive rhabdomyosarcoma
  • PBTC-029
  • PEPCTN_NonCoreStudyStartup_WLI
  • PEPCTN_PCR
  • PKD Natural Study
  • PROTOCOL AG348-C-008 Pyruvate Kinase Deficiency Global Longitudinal Registry
  • Pediatric Brain Tumor Consortium
  • Pediatric Hydroxyurea Phase III Clinical Trial (Baby Hug): Follow-Up Observational Study II
  • Pediatric Oncology Group
  • Pediatric Oncology Group Studies
  • Pediatric Oncology Group Studies
  • Pediatric Oncology Group Studies
  • Pediatric Oncology Group Studies
  • Pediatric Oncology Group Studies
  • Pediatric Oncology Group Studies
  • Per Case Reimbursement : NIH National Clinical Trials Network (NCTN)
  • Per Case Reimbursement : NIH National Clinical Trials Network (NCTN)
  • Phase I Trial Of 06-Benzylguanine Plus Bcnu In Glioma
  • Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors.
  • Pratt Cares Program
  • Pre-clinical studies of CDK8 human fusion-positive rhabdomyosarcoma
  • Preclinical studies of NUAK kinase inhibitors in fusion-positive rhabdomyosarcoma
  • Project: One Time EOY, Integrated BIQSFP AAML1031- Echocardiogram Reports and Images
  • Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and other Clinical Conditions Treated with Emapalumab across Treatment Centers in the US (REAL-HLH Study)
  • Role of MST/Hippo kinase inactivation in driving fusion-positive rhabdomyosarcoma
  • Role of the macro lncRNA KCNQ1OT1 in embryonal rhabdomyosarcoma tumorigenesis
  • Role of the macro lncRNA KCNQ1OT1 in embryonal rhabdomyosarcoma tumorigenesis
  • SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
  • STUDY CHAIR: NIH National Clinical Trials Network (NCTN) Grant
  • Specimen Banking Supplements
  • St. Baldrick's Summer Fellow Grant
  • Study Chair: COG NCTN Network Group Operations Center
  • Study on caplacizumab-treated pediatric patients
  • TCD With Transfusions Changing to Hydroxyurea (TWITCH) Closeout
  • Targeting CDK8 in fusion-positive rhabdomyosarcoma
  • Targeting p53 in childhood rhabdomyosarcoma
  • Targeting the Hippo pathway in Ras-driven rhabdomyosarcoma
  • The role of H3K27M-induced aberrant PRC2 activity in brainstem gliomagenesis
  • The role of MEST (mesoderm specific transcript) in rhabdomyosarcoma
  • The role of MST1 in non-canonical Hippo signaling in rhabdomyosarcoma
  • The secreted protein SFRP3 as a therapeutic target in rhabdomyosarcoma
  • Therapeutic potential and use of novel CRISPR technology for lncRNA knockdown in rhabdomyosarcoma
  • Transplant Centers For Clinical Research On
  • VAL-10-001: Pilot Pharmacokinetic Study of VAL-413 in Patients with Recurrent Pediatric Solid Tumors
  • Validating a mouse model of rhabdomyosarcoma
  • Visual Field Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas
  • Workload Intensity NIH National Clinical Trials Network (NCTN)
  • Workload Intensity NIH National Clinical Trials Network (NCTN)

Add data to my Website